<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: We previously demonstrated that a modified fatty acid, tetradecylthioacetic acid (TTA), improves transport and utilization of <z:chebi fb="23" ids="18059">lipids</z:chebi> and increases <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> fatty acid oxidation in animal and cell studies </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted an exploratory study of safety and effects of this novel drug in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and investigated the mechanism of action in human cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Sixteen male patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> received 1 g TTA daily for 28 days in an open-labelled study, with measurement of parameters of <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism, <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and safety (ClinicalTrials.gov NCT00605787) </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanism of action was further investigated in a human liver cell line (HepG2) and in cultured human skeletal muscle cells (myotubes) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> level declined from 4.2 to 3.7 mmol/l (p &lt; 0.001), accompanied by increased levels of the <z:chebi fb="17" ids="39025">HDL</z:chebi> <z:chebi fb="0" ids="39015">apolipoproteins</z:chebi> A1 and A2, and a decline in <z:chebi fb="15" ids="39026">LDL</z:chebi>/<z:chebi fb="17" ids="39025">HDL</z:chebi> ratio from 4.00 to 3.66 (p = 0.008) </plain></SENT>
<SENT sid="5" pm="."><plain>Total fatty acid levels declined, especially the fraction of the polyunsaturated n-3 fatty acids <z:chebi fb="0" ids="36005">docosahexaenoic acid</z:chebi> (-13%, p = 0.002) and eicosapentaenoic acid (-10%, p = 0.07) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> metabolism was not altered and the drug was well tolerated </plain></SENT>
<SENT sid="7" pm="."><plain>In cultured liver cells, TTA acted as a pan-PPAR <z:chebi fb="4" ids="48705">agonist</z:chebi> with predominant PPAR-alpha and PPAR-delta activation at low TTA concentrations </plain></SENT>
<SENT sid="8" pm="."><plain>In myotubes, TTA and a PPAR-delta <z:chebi fb="4" ids="48705">agonist</z:chebi>, but not the PPAR-alpha or PPAR-gamma <z:chebi fb="4" ids="48705">agonists</z:chebi>, increased the fatty acid oxidation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We demonstrate for the first time that TTA attenuates <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>These effects may occur through mechanisms involving PPAR-alpha and PPAR-delta activation, resulting in increased <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> fatty acid oxidation </plain></SENT>
</text></document>